COVID-19 and Coagulopathy

Yıl 2020, Cilt: 1 Sayı: 2, 65 - 68, 30.09.2020

Zafer Gökgöz Aykut İlker Arslan

https://doi.org/10.1016/j.blre.2020.100707

Öz

The virus, severe acute respiratory syndrome coronavirus 2 SARSCoV-2 , which is thought to have emerged in Wuhan city of China for the first time in December 2019, was named by The World Health Organization WHO , and the disease it caused was called coronavirus disease 19 COVID-19 . Although it has emerged as a respiratory pathogen, SARS-CoV-2, the first pandemic of the 21st century, has been shown to affect the central nervous system, heart, kidneys and vascular structures and coagulation system in a short period of time despite the limited number of cases . Even though the picture resulting from the effects of the virus on the coagulation system is similar to that of common intravascular coagulation or sepsis, it includes significant points in differential diagnosis. Anticoagulant treatments should be administered to patients in prophylactic or treatment doses due to their susceptibility to coagulation. In this review, the effects of COVID-19 on coagulation and the management of the process will be examined.

Anahtar Kelimeler

SARS-Cov2, COVID-19, coagulation

COVID-19 ve Koagülopati

Öz

2019 yılı Aralık ayında ilk defa Çin’in Wuhan kenti’nde ortaya çıktığı düşünülen virüse; Dünya Sağlık Örgütü DSÖ tarafından şiddetli akut solunum yolu sendromu koronavirüs 2 SARS-CoV-2 adı, yaptığı hastalığa ise koronavirus hastalığı 19 COVID-19 adı verildi. 21. Yüzyılın ilk pandemisi olan SARS-CoV-2 öncelikle solunum yolları patojeni gibi ortaya çıkmış olmasına karşı kısa sürede yapılan yayınlarda her ne kadar vaka sayıları sınırlı olsa da santral sinir sistemini, kalbi, böbrekleri ve vasküler yapıları ve koagülasyon sistemini de etkilediği gösterildi. Koagulasyon sistemi üzerinde virusun etkileri sonucu ortaya çıkan tablo her ne kadar yaygın damar içi pıhtılaşma ya da sepsistekine benzer olsa da ayırıcı tanıda önemli noktaları içermektedir. Koagulasyona yatkınlık nedeniyle hastalara antikoagulan tedaviler profilatik ya da tedavi dozunda uygulanmalıdır. Bu derleme de COVID-19’un koagülasyon sistemi üzerine etkilerini ve mevcut literatüre göre tedavi önerilerini irdeleyeceğiz.

Anahtar Kelimeler

SARS-Cov2, COVID-19, koagulasyon

Kaynakça

• Roujian L, Xiang Z, Juan L, Peihua N, Bo Y, Honglong W et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395 10224 : 565-574.
• Iba T, Levy JH, Thachil J, Wada H, Levi M. Scientific and Standardization Committeeon DIC of the International Society on Thrombosis and Haemostasis. The progres-sion from coagulopathy to disseminated in-travascular coagulation in representativeunderlying diseases.Thromb Res. 2019;179:11-14.
• Nanshan C, Min Z, Xuan D, Jieming Q, Fengyun G, Yang H, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet. 2020;395 10223 :507-513.
• Dawei W, Bo H, Chang H,Fangfang Z, Xing L, Jing Z, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus- infected pneumonia in Wuhan, China.JAMA. 2020;323 11 :1061-1069
• Menter T, Haslbauer JD, Nienhold R, Spasenija S, Helmut H, Nikolaus D, et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology 2020.
• Wichmann D, Sperhake JP, Lütgehetmann M, Stefan S, Carolin E, Axel H et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 2020.
• England JT, Abdulla A, Biggs CM, Agnes Y Y Lee , Kevin A Hay , Ryan L H et al. Weathering the COVID-19 storm: Lessons from hematologic cytokine syndromes. Blood Reviews. 2020; doi: 10.1016/j.blre.2020.100707
• Engelmann B, Massberg S. Thrombosis as anintravascular effector of innate immunity.NatRev Immunol. 2013;13 1 :34-45.
• Chen G, Wu D, Guo W, Yong C , Da H , Hongwu W et al. Clinical and Immunologic features in severe and moderate coronavirus disease 2019 [published onlineahead of print 27 March 2020].J Clin Invest.doi:10.1172/ JCI137244.
• Levi M, Scully M. How I treat disseminatedintravascular coagulation.Blood. 2018;131 8 :845-854.
• Ranucci M, Ballotta A, Di Dedda U, Ekaterina B Marco DP Marco R et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome [pub-lished online ahead of print 17 April 2020].J Thromb Haemost. doi:10.1111/jth.14854.
• Magro C, Mulvey JJ, Berlin D, Gerard N, Steven S, Joanna H et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020.
• Panigada M, Bottino N, Tagliabue P, Giacomo G, Cristina N, Veena C et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost 2020.
• Ranucci M, Ballotta A, Di Dedda U, Ekaterina B, Marco D, Marco R, Mara F. et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 2020.
• Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020; 18:844.
• Amgalan A, Othman M. Exploring possible mechanisms for COVID-19 induced thrombocytopenia: Unanswered questions. J Thromb Haemost 2020.
• Helms J, Tacquard C, Severac F, Ian L, Mickaël O, Xavier D, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020.
• Middeldorp S, Coppens M, van Haaps TF, Merijn F, Alexander P V, Marcella M et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020.
• Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020.
• http://www.onlinejacc.org/content/early/2020/05/05/j.jacc.2020.05.001.
• Tang N, Bai H, Chen X, Jiale G, Dengju L, Ziyong S al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18:1094.